Injectable in situ forming microparticles: A novel drug delivery system

Tropical Journal of Pharmaceutical Research

Volumn 11, Issue 2, 2012, Pages 307-318

  Yapar, Evren Algin ^a   Inal, Özge ^b   Özkan, Yalçin ^c   Baykara, Tamer ^d  

^a MINISTRY OF HEALTH   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

^d BILKENT UNIVERSITY   (Turkey)

Author keywords

Controlled drug delivery; In situ forming; Injectable; Microparticle system

Indexed keywords

BUPIVACAINE; DILTIAZEM; HALOPERIDOL; LEUPRORELIN; MICROSPHERE; MONTELUKAST; OIL; RISPERIDONE;

CLINICAL EFFECTIVENESS; CONCENTRATION (PARAMETERS); CONTROLLED DRUG RELEASE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MICROENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHASE SEPARATION; PROCESS DEVELOPMENT; REPRODUCIBILITY; REVIEW; SURFACE PROPERTY; TOXICITY TESTING;

EID: 84859997973     PISSN: 15965996     EISSN: 15969827     Source Type: Journal    
DOI: 10.4314/tjpr.v11i2.19     Document Type: Review

References (47)

1. Benoit JP, Marchais H, Rolland H, Vande-Velde V. Biodegradable microspheres: advances in production technology. In Benita, S, Ed. Microencapsulation methods and industrial applications. New York: Marcel Dekker; 1996; pp 35-72.
2. Rothen-Weinhold A, Besseghir K, Vuaridel E, Sublet E, Oudry N, Kubel F, Gurny R. Injection-molding versus extrusion as manufacturing technique for the preparation of biodegradable implants. Eur J Pharm Biopharm 1999; 48: 113-121.
3. Jalil R, Nixon JR. Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties. J Microencapsulation 1990; 7: 297-325.
4. Tice TR, Tabibi ES. Parenteral drug delivery: injectables. In Kydonieus, A, editor. Treatise on controlled drug delivery: Fundamentals optimization, applications. New York: Marcel Dekker; 1991; 1991; pp 315-339.
5. Wu XS. Synthesis and properties of biodegradable lactic/glycolic acid polymers. In: Wise DL; Trantolo DJ; Altobelli DE; Yaszemski MJ; Gresser JD; Schwartz ER, editors. Encyclopedic handbook of biomaterials and bioengineering. Part A: Materials, New York: Marcel Dekker; 1995; pp 1015-1054.
6. Wu XS. Preparation, characterization, and drug delivery applications of microspheres based on biodegradable lactic/glycolic acid polymers. In: Wise DL; Trantolo DJ; Altobelli DE; Yaszemski MJ; Gresser JD; Schwartz ER, editors. Encyclopedic handbook of biomaterials and bioengineering. Part A: Materials, New York: Marcel Dekker; 1995; pp 1151-1200.
7. Lewis DH. Controlled release of bioactive agents from lactide/glycolide polymers. In Chasin M; Langer R, editors. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker; 1990; pp 1-41.
8. Schultz K, Mollgaard B, Fisher AN, Illum L, Larsen C. Intramuscular rate of disappearance of oily vehicles in rabbits investigated by gammascintigraphy. Int J Pharm 1998; 169: 121-126.
9. Bjerregaard S, Pedersen H, Vedstesen H, Vermehren C, Söderberg I, Frokjaer S. Parenteral water/oil emulsions containing hydrophilic compounds with enhanced in vivo retention: formulation, rheological characterization and study of in vivo fate using whole body gamma-scintigraphy. Int J Pharm 2001; 215: 13-27.
10. Bjerregaard S, Pedersen H, Wulf-Andersen L, Stephens RW, Lund LR, Vermehren C, Söderberg I, Frokjaer S. Sustained elevated plasma aprotinin concentration in mice following intraperitoneal injections of w/o emulsions incorporating aprotinin. J Control Release 2001; 71: 87-98.
11. Dunn RL, English JP, Cowsar DR, Vanderbilt DP. Biodegradable in-situ forming implants and methods of producing the same. US Patent 4938763, 1990. http://www.google.com/patents/about/4938763_Biodegradable_in_situ_formin g_im.html?id=DRYmAAAAEBAJ Accessed 27 July, 2011. Available from: http://www.patents.com/us-4938763.html
12. Tipton AJ, Fujita SM. A biodegradable injectable delivery system for nonsteroidal antiinflammatory drugs. Pharm Res 1991; 9 (Suppl): S-196.
13. Shah NH, Railkar AS, Chen FC, Tarantino R, Kumar S, Murjani M, Palmer D, Infeld MH, Malick AW. A biodegradable injectable implant for delivering micro and macromolecules using poly (lactic-co-glycolic) acid (PLGA) copolymers. J Control Release 1993; 27: 139-147.
14. Coonts BA, Lowe BK, Norton RL, Tipton AJ, Yewey GL, Dunn RL. Plasma concentrations of naltrexone following subcutaneous and intramuscular injections of Atrigel™ formulations in dogs. Pharm Res 1993; 10: S-192.
15. Duysen EG, Yewey GL, Southard JL, Dunn RL, Huffer W. Release of bioactive growth factors from the Atrigel delivery system in tibial defect and dermal wound models. Pharm Res 1993; 10: S-83.
16. Lambert WJ, Peck KD. Development of an in-situ forming biodegradable poly-lactide-coglycolide system for the controlled release of proteins. J Control Release 1995; 33: 189-195.
17. Radomsky ML, Brouwer G, Floy BJ, Loury DJ, Chu F, Tipton AJ, Sanders LM. The controlled release of ganirelix from the Atrigel™ injectable implant system. Proc Int Symp Control Rel Bioact Mater 1993; 20: 458-459.
18. Alǧin-Yapar E, Ari N, Baykara T. Investigation of in vitro and in vivo performance of injectable in situ implants. Turkish J Pharm Sci 2010; 7(1): 9-20.
19. Ahmed TA, Ibrahim HM, Ibrahim F, Samy AM, Kaseem A, Nutan MT, Hussain MD. Development of injectable in situ implant and microparticle formulations for controlled delivery of montelukast. AAPS Journal 2010; 12: 78 (S2). www.aapsj.org/abstracts/AM_2010/R6278.pdf Accessed 05 August, 2011
20. Ahmed TA, Ibrahim HM, Khalifa S, Samy AM, Kaseem A, Nutan MT, Hussain MD. Controlled release of haloperidol from biodegradable injectable in situ implant and microparticle formulations. AAPS Journal 2010; 12: 77 (S2). www.aapsj.org/abstracts/AM_2010/R6277.pdf. Accessed 05 August 2011.
21. Wischke C, Zhang Y, Mittal S, Schwendeman SP. Development of PLGA-based injectable delivery systems for hydrophobic fenretinide. Pharm Res 2010; 27: 2063-2074. (DOI 10.1007/s11095-010-0202-y)
22. Higuchi T. Mechanism of sustained-action medication. J Pharm Sci 1963; 52: 1145-1149.
23. Alǧin-Yapar E, Baykara T. Effects of variations in formulation components on drug release from injectable in situ implants. Med Sci Tech Res 2009; 2(2): 21-29.
24. Alǧin-Yapar E, Baykara T. Effects of solvent combinations on drug release from injectable phase sensitive liquid implant systems. Turkish J Pharm Sci 2010; 7(1): 47-54.
25. Eliaz RE, Kost J. Characterization of a polymeric PLGA-injectable implant delivery system for controlled release of proteins. J Biomed Mater Res 2000; 50: 388-396.
26. McHugh AJ. The role of polymer membrane formation in sustained release drug delivery systems. J Control Release 2005; 109: 211-221.
27. Bakhshi R, Vasheghani-Farahani E, Mobedi H, Jamshidi A, Khakpour M. The effect of additives on naltrexone hydrochloride release and solvent removal rate from an injectable in situ forming PLGA implant. Polym Adv Technol 2006; 17: 354-359.
28. Bodmeier R. Verfahren zur in-situ Herstellung von Partikeln. Offenlegungsschrift, DE. Patent 1997; 197,24,784.
29. Kranz H, Bodmeier R. A biodegradable in-situ forming system for controlled drug release. Pharm Sci 1998; 1 (Suppl): 414.
30. Rungseevijitprapa W, Bodmeier R. Injectability of biodegradable in situ forming microparticle systems (ISM). Eur J Pharm Sci 2009; 36(4-5): 524-531.
31. Luan X, Bodmeier R. In situ forming microparticle system for controlled delivery of leuprolide acetate: influence of the formulation and processing parameters. Eur J Pharm Sci 2006; 27: 143-149.
32. Luan X, Bodmeier R. Influence of the poly(lactideco- glycolide) type on the leuprolide release from in situ forming microparticle systems. J Control Release 2006; 110: 266-272.
33. Kranz H, Bodmeier R. A novel in situ forming drug delivery system for controlled parenteral drug delivery. Int J Pharm 2007; 332: 107-114.
34. Kranz H, Brazeau GA, Napaporn J, Martin RL, Millard W, Bodmeier R. Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems. Int J Pharm 2001; 212: 11-18.
35. Jain RA, Rhodes CT, Railkar AM, Malick AW, Shah NH. Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables. Eur J Pharm Biopharm 2000; 50(2): 257-262.
36. Kranz H, Bodmeier R. Structure formation and characterization of injectable drug loaded biodegradable devices: In situ implants versus in situ microparticles. Eur J Pharm Sci 2008; 34: 164-172.
37. Kranz H, Yilmaz E, Brazeau GA, Bodmeier R. In vitro and in vivo drug release from a novel in situ forming drug delivery system. Pharm Res 2008; 25(6): 1347-1354. (DOI: 10.1007/s110 95-007-9478-y.)
38. Jain RA. The manufacturing techniques of various drug-loaded biodegradable poly(lactide-coglycolide) (PLGA) devices. Biomaterials 2000; 21: 2475-2490.
39. Rungseevijitprapa W, Brazeau GA, Simkins JW, Bodmeier R. Myotoxicity studies of O/W-in situ forming microparticle systems. Eur J Pharm Biopharm 2008; 69(1): 126-133.
40. Jain RA, Rhodes CT, Railkar AM, Malick AW, Shah NH. Comparison of various injectable proteinloaded biodegradable poly(Lactide-coglycolide) (PLGA) devices: in-situ-formed implant versus in-situ-formed microspheres versus isolated microspheres. Pharm Dev Tech 2000; 5(2): 201-207.
41. Jain RA, Rhodes CT, Railkar AM, Malick AW, Shah NH. Controlled release of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system. Pharm Sci 1998; 1(Suppl): 1298.
42. Jain RA, Rhodes CT, Railkar AM, Malick AW, Shah NH. Comparision of various protein loaded biodegradable PLGA devices. Proceedings of the International Symposium on Control Rel Bioact Mater 1999; p 26.
43. Jain R. In situ microencapsulation. [PhD dissertation]. [Kingston, Rhode Island]: The University of Rhode Island, 1998.
44. Körber M, Bodmeier R. Development of an in situ forming PLGA drug delivery system I. Characterization of a non-aqueous protein precipitation. Eur J Pharm Sci 2008; 35: 283-292.
45. Dong WY, Körber M, Esguerra LV, Bodmeier R. Stability of poly(D,L- lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems. J Control Release 2006; 115: 158-167.
46. Ibrahim HM, Ahmed TA, Ismail HR, Samy AM, Kaseem AA, Hussain MD, Nutan MT. Development of extended release biodegradable injectable in situ microparticle formulation of meloxicam. AAPS Journal 2010; 12: 89. (S2). Available from: www.aapsj.org/abstracts/AM_2010/R6289.pdf www.aapsj.org/abstracts/AM_2010/R6289.pdf. Accessed 05 August 2011.
47. Prolonged Release Injectable Formulations. Rovi Pharmaceuticals. [Homepage on the Internet] http://www.rovi.es/id_formulaciones_english.html. Accessed 06 August 2011.